Welcome to to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
Yes
No
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

December 21, 2014

Constipation in Adults

Download pdf – Constipation is defecation that is unsatisfactory because of infrequent stools, difficult stool passage, or seemingly incomplete defecation. Stools are often dry and hard, and may be abnormally large or abnormally small. Functional constipation is chronic constipation without a known cause. Secondary constipation is caused by a drug or medical condition (such as […]

Kellogg’s All-Bran – Effective Natural Relief for Constipation and Digestive Discomfort

Download pdf Slow digestive transit and constipation are common complaints estimated to affect around one third of adults.1 In 2012, almost 900,000 prescriptions were issued to the Irish population, at a cost of more than 7 million Euros.2 Increasing fibre intake is a core recommendation for the treatment of constipation3, and wheat bran is an […]

Agomelatine (Valdoxan) – Reminder of the Importance of Liver Function Monitoring to Reduce the Risk of Serious Hepatic Adverse Reactions

Agomelatine* is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, indicated in the treatment of major depressive episodes in adults. It was first authorised for use across the EU since 2009 on the basis of studies showing that the medicine has comparable effects to other antidepressants.  Since agomelatine has a different mode of […]

Invokana ▼

Company: Janssen-Cilag Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Canagliflozin 100mg, 300mg. Description: Yellow or white, capsule-shaped, immediate-release, film-coated tablets, marked CFZ on one side and strength on reverse, respectively. Presentation: 100mg-30, €41.70; 300mg-30, €57.60. Indication: Treatment of type 2 diabetes mellitus. As monotherapy when diet and exercise alone do not provide adequate […]

Nicochew Mint

Company: Clonmel Healthcare Ltd. Legal category: Sport permitted. Active ingredient: Nicotine (as resinate) 2mg, 4mg. Description: White to yellowish, slightly convex, rectangular medicated chewing-gum. Presentation: 2mg, €5.67; 4mg, €7.06. Indications: Treatment of tobacco dependence by relieving nicotine withdrawal symptoms including cravings, to facilitate smoking cessation or temporary smoking reduction in smokers motivated to quit. Pharmacology: […]

Xeomin

Company: Merz Pharma UK Ltd. Legal category: Prescription. Sport permitted. Active ingredient: Clostridium Botulinum neurotoxin type A 50 LD50 units, 100 LD50 units. Description: Powder for solution for injection. Presentation: 50U-1 vial, €110.00; 100U-1 vial, €195.00. Indications: Symptomatic treatment of blepharospasm, spasmodic torticollis and post-stroke spasticity of the upper limb. Pharmacology: Botulinum neurotoxin type A […]

Spiriva Respimat – New Indication for Treatment of Asthma

Download pdf Spiriva Respimat (tiotropium) is now indicated for add-on maintenance bronchodilator treatment in adults with asthma currently treated with inhaled corticosteroids (≥800mcg daily of budesonide or equivalent) and long-acting ß2 agonists (LABAs) and who experienced one or more severe exacerbations in the previous year.1 It is already licensed for maintenance bronchodilator treatment in patients […]

Jardiance ▼ – Approved for Treatment of Type 2 Diabetes

Download PDF Boehringer Ingelheim Ireland Ltd. and Eli Lilly and Co. Ireland Ltd. are pleased to announce that Jardiance (empagliflozin) has been granted European marketing authorisation for the treatment of type 2 diabetes. Empagliflozin is a potent and selective inhibitor of sodium-glucose co-transporter 2 (SGLT2) which is predominantly responsible for renal glucose reabsorption. Empagliflozin acts […]

Individualised Therapy in Type 2 Diabetes

Download PDF The Global Partnership for Effective Diabetes Management advocates an individualised therapeutic approach and has identified specific type 2 diabetes patient subgroups that require special consideration and proposed practical advice for setting glycaemic targets and tailoring treatment management for these groups. A patient-centred approach has also been recommended by several other organisations, such as […]

New Treatment Option for Type 2 Diabetes – SGLT2 Inhibitors

Download PDF Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of drugs indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults aged ≥18 years as monotherapy when diet and exercise alone do not provide adequate glycaemic control when use of metformin considered inappropriate due to intolerance, or […]

Next Page »